Peripheral cancer attenuates amyloid pathology in Alzheimer’s disease via cystatin-c activation of TREM2

2026/01/22 by Xinyan Li, Xiaomei Tang, Jinyu Zeng +14 · 2 voices
Immunology and Microbiology · Neuroscience · #Inflammation biomarkers and pathways #Neuroinflammation and Neurodegeneration Mechanisms #Neurological Disease Mechanisms and Treatments

paper · doi:10.1016/j.cell.2025.12.020

openalex publication_date 2026/01/22 · crossref created 2026/01/22 · openalex created_date 2026/01/23 · crossref issued 2026/02/01 · crossref published 2026/02/01 · crossref published-print 2026/02/01 · crossref deposited 2026/05/13 · crossref indexed 2026/07/27 · openalex updated_date 2026/07/31

Citations

• Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families
• <i>TREM2</i> Variants in Alzheimer's Disease
• Roles of tau protein in health and disease
• Alzheimer's disease
• Lecanemab in Early Alzheimer’s Disease

Discussions

• "we find that peripheral cancer inhibits amyloid pathology & rescues cognition via secretion of cystatin-c, which binds amyloid oligomers & activates triggering receptor expressed on myeloid cells 2 i [bsky, 1 points, 1 comments]
• How surprising: doi.org/10.1016/j.ce... It started with an observation that people with cancer rarely get Alzheimer's disease. It turns out that tumors secrete cystatin C, which blocks plaque formati [bsky, 0 points, 0 comments]